RLYB News and Press, Rallybio Corporation From 03/02/26

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investor...

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topli...

2026-02-03 16:23:42 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio to implement ...

Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect the rever...

2025-11-06 12:34:58 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio GAAP EPS of $...

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology c...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 – – Data Readouts for Completed Study Expected in 4Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company t...

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – – Extends Cash Runway through 2027 – Rallybio Corporation (Nasdaq: RLYB), a clin...

2025-08-12 09:27:16 ET Las Vegas, NV – August 12, 2025 – Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions, and its Joint Venture partner, Ainnova Tech, Inc. (Ainnova...